文献速递脑血管病

高敏肌钙蛋白T用于不明来源栓塞性卒中风险分层

High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source.
PubMed 文献 · Stroke · 2020-07-09

本研究基于NAVIGATE ESUS试验的生物标志物子研究,纳入1337例不明来源栓塞性卒中(ESUS)患者,评估高敏肌钙蛋白T(hs-cTnT)与主要血管事件的关系及对抗凝获益的识别作用。结果显示hs-cTnT与心血管事件率升高相关,但未能分层抗凝治疗结局。

要点

  • hs-cTnT可帮助ESUS患者进行心血管风险分层。
  • hs-cTnT水平不能用于指导ESUS抗凝治疗决策。
  • 利伐沙班较阿司匹林减少复发性缺血性卒中。

核心结论

  • 在ESUS患者中,hs-cTnT与心血管事件率升高相关,但不支持用其指导抗凝治疗决策。

研究设计与样本

  • NAVIGATE ESUS试验的生物标志物子研究,随机对照试验,纳入1337例ESUS患者,来自18个国家111个中心,平均年龄67±9岁,61%男性。

主要发现

  • hs-cTnT可检测率为95%,≥上限参考限(14 ng/L)者占21%。
  • 中位随访11个月,复合心血管终点发生68例(5.0%/年),复发性缺血性卒中发生50例(4.0%/年)。
  • hs-cTnT≥上限参考限者复合心血管终点年化率为8.2%,低于上限参考限者为4.8%,治疗交互作用显著(P=0.04)。
  • 复发性缺血性卒中年化率在hs-cTnT≥上限参考限者为4.7%,低于上限参考限者为3.9%,无治疗交互作用(P=0.3)。

关键数值与推荐

  • hs-cTnT上限参考限为14 ng/L(Gen V, Roche Diagnostics)。
  • 复合心血管终点:利伐沙班28例 vs 阿司匹林40例,HR 0.67(95%CI 0.41-1.1)。
  • 复发性缺血性卒中:利伐沙班16例 vs 阿司匹林34例,HR 0.45(95%CI 0.25-0.81)。

临床怎么用

  • 可使用hs-cTnT对ESUS患者进行心血管风险分层。
  • 不应根据hs-cTnT结果决定是否启动抗凝治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Optimal secondary prevention for patients with embolic stroke of undetermined source (ESUS) remains unknown. We aimed to assess whether high-sensitivity cardiac troponin T (hs-cTnT) levels are associated with major vascular events and whether hs-cTnT may identify patients who benefit from anticoagulation following ESUS. METHODS: Data were obtained from the biomarker substudy of the NAVIGATE ESUS trial, a randomized controlled trial testing the efficacy of rivaroxaban versus aspirin for secondary stroke prevention in ESUS. Patients were dichotomized at the hs-cTnT upper reference limit (14 ng/L, Gen V, Roche Diagnostics). Cox proportional hazard models were computed to explore the association between hs-cTnT, the combined cardiovascular end point (recurrent stroke, myocardial infarction, systemic embolism, cardiovascular death), and recurrent ischemic stroke. RESULTS: Among 1337 patients enrolled at 111 participating centers in 18 countries (mean age 67±9 years, 61% male), hs-cTnT was detectable in 95% and at/above the upper reference limit in 21%. During a median follow-up of 11 months, the combined cardiovascular end point occurred in 68 patients (5.0%/y, rivaroxaban 28 events, aspirin 40 events; hazard ratio, 0.67 [95% CI, 0.41-1.1]), and recurrent ischemic stroke occurred in 50 patients (4.0%/y, rivaroxaban 16 events, aspirin 34 events, hazard ratio 0.45 [95% CI, 0.25-0.81]). Annualized combined cardiovascular end point rates were 8.2% (9.5% rivaroxaban, 7.0% aspirin) for those above hs-cTnT upper reference limit and 4.8% (3.1% rivaroxaban, 6.6% aspirin) below with a significant treatment modification (P=0.04). Annualized ischemic stroke rates were 4.7% above hs-cTnT upper reference limit and 3.9% below, with no suggestion of an interaction between hs-cTnT and treatment (P=0.3). CONCLUSIONS: In patients with ESUS, hs-cTnT was associated with increased cardiovascular event rates. While fewer recurrent strokes occurred in patients receiving rivaroxaban, outcomes were not stratified by hs-cTn results. Our findings support using hs-cTnT for cardiovascular risk stratification but not for decision-making regarding anticoagulation therapy in patients with ESUS. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Scheitz JF, Pare G, Pearce LA, et al. High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. Stroke. 2020. PMID: 32640945. doi:10.1161/STROKEAHA.120.029628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。